These differences in the angiogenic microenvironment between hepatic metastases and the primary colorectal tumor have resulted in anti-VEGF treatment to be used only in metastatic disease and may thus also explain the different effects of PlGF in different disease stages. Here, PGF is linked to metastatic neoplasm.